PRNewsWire
03 Jun 2026, 01:20 UTC · 15w ago
Verdict
Headline leans bearish. We score ABVX −1.00 across three claims.
Score confirms the headline.
Leans bearish
From its wording — no explicit rating
−1.00strongly bearish
What the story claims
3 claims · scored −1 bearish … +1 bullish
Rare malignancy cases emerged in Abivax's Phase 3 ABTECT ulcerative colitis trial for obefazimod.
More negative than 99% of claims this week
Jefferies downgraded Abivax from Buy to Hold and reduced its price target from $160 to $90.
So whatA significant downgrade and a 44% target cut by a major analyst reflect a fundamental shift in valuation and institutional sentiment.
Continue reading
5 related stories
More negative than 96% of ticker scores this week
Scored by the NIS engine · methodology.
Top 1 mover · tap to explore
More negative than 92% of claims this week
SueWallSt has initiated an investigation into whether Abivax adequately disclosed material safety risks associated with the Phase 3 trial.
More negative than 81% of claims this week
Which stocks this story touches
More negative than 96% of ticker scores this week
The company's stock plummeted over 40% following reports of rare cancer cases in a Phase 3 clinical trial and a subsequent analyst downgrade.
More negative than 87% of ticker scores this week
The company is mentioned as being under investigation after shareholders lost approximately 23.4% of their holdings in a single session.
More negative than 84% of ticker scores this week
The company reported Q1 results that led to a more than 15% loss in investment value for shareholders over two days.
Free · No account
Get a free daily PDF briefing — the last 24 hours of news, with summaries and the market-impact score for each story, delivered an hour before the open.
We’ll watch
Pre-filled from this story — remove any you don’t want. Add more tickers & tags or fine-tune your watchlist anytime — every email has an edit link, no account needed.
Free forever · one email a day, max · unsubscribe in one click.How it works
24/7 Wall Street
2d ago
+44.9%
Price is moving against the score
$105.04 vs $72.50 close before publication (Jun 2) · not market-adjusted
ABVX chart →
